gene in patients relapsing immediately after therapy Along with the BCL2 antagonist venetoclax. 66 Resistance to those brokers has actually been connected with these mutations in all around 70% of conditions, While they are generally subclonal as well as their distinct role triggering resistance must be proven.??? "?????????????????????????????????